Antibody responses to A/17/mallard/Netherlands/00/95 (H7N3) LAIV.

1The HAI antibody GMT after second vaccination was statistically significantly higher than pre–vaccination GMT (Wilcoxon Matched Pairs Test with Bonferroni adjustment: p = 0,0024);
2There was no statistically significant difference between serum HAI antibody GMTs at three time points in placebo group (Friedman ANOVA: ANOVA Chi Sqr. (N = 10, df = 2) = 0,6667, p = 0,7165);
3The HAI antibody GMT after first vaccination was statistically significantly higher than pre–vaccination GMT (Wilcoxon Matched Pairs Test with Bonferroni adjustment: p = 0,0012);
4The HAI antibody GMT after second vaccination was statistically significantly higher than pre–vaccination GMT (Wilcoxon Matched Pairs Test with Bonferroni adjustment: p = 0,0004);
5There was no statistically significant difference between serum HAI antibody GMTs at three time points in placebo group (Friedman ANOVA: ANOVA Chi Sqr. (N = 10, df = 2) = 2,6667; p = 0,2636);
6The serum neutralizing antibody GMT after first vaccination was statistically significantly higher than pre–vaccination GMT (Wilcoxon Matched Pairs Test with Bonferroni adjustment: p = 0,0166);
7The serum neutralizing antibody GMT after second vaccination was statistically significantly higher than pre–vaccination GMT (Wilcoxon Matched Pairs Test with Bonferroni adjustment: p = 0,0001);
8The serum neutralizing antibody GMT after second vaccination was statistically significantly higher than GMT after first vaccination (Wilcoxon Matched Pairs Test with Bonferroni adjustment: p = 0,0025);
9There was no statistically significant difference between serum neutralizing antibody GMTs at three time points in placebo group (Friedman ANOVA: ANOVA Chi Sqr. (N = 10, df = 2) = 2,000, p = 0,3679);
10There was no statistically significant difference between serum IgG GMTs at three time points in vaccinated group (Friedman ANOVA: ANOVA Chi Sqr. N = 29, df = 2) = 0,2222, p = 0,8948);
11There was no statistically significant difference between serum IgG GMTs at three time points in placebo group (Friedman ANOVA: ANOVA Chi Sqr. (N = 10, df = 2) = 3,000, p = 0,2231);
12The serum IgA GMT after second vaccination was statistically significantly higher than pre–vaccination GMT (Wilcoxon Matched Pairs Test with Bonferroni adjustment: p = 0,0157);
13There was no statistically significant difference between serum IgA GMTs at three time points in placebo group (Friedman ANOVA: ANOVA Chi Sqr. (N = 10, df = 2) = 2,6667, p = 0,2636);
14The mucosal IgA GMT after first vaccination was statistically significantly higher than pre–vaccination GMT (Wilcoxon Matched Pairs Test with Bonferroni adjustment: p = 0,0031);
15There was no statistically significant difference between mucosal IgA GMTs at three time points in placebo group (Friedman ANOVA: ANOVA Chi Sqr. (N = 10, df = 2) = 0,3077, p = 0,8574);
16Percent with ≥fourfold HAI antibody titer rise after two doses of LAIV A(H7N3) was statistically significantly higher than in placebo group (Fisher exact (two–tailed) p = 0,0161).
17Percent with ≥four fold serum neutralizing antibody titer rise after two doses of LAIV A(H7N3) was statistically significantly higher than in placebo group (Fisher exact (two–tailed) p = 0,0172).